Explainable Machine Learning Predictions for the Benefit From Chemotherapy in Advanced Non‐Small Cell Lung Cancer Without Available Targeted Mutations
ABSTRACT Background Non‐small cell lung cancer (NSCLC) is a global health challenge. Chemotherapy remains the standard therapy for advanced NSCLC without mutations, but drug resistance often reduces effectiveness. Developing more effective methods to predict and monitor chemotherapy benefits early i...
Saved in:
| Main Authors: | Zhao Shuang, Xiong Xingyu, Cheng Yue, Yu Mingjing |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | The Clinical Respiratory Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/crj.70044 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Meta‐Analysis of Efficacy and Safety of Neoadjuvant Immunotherapy Plus Chemotherapy for Resectable Non‐Small Cell Lung Cancer
by: Xinru Sun, et al.
Published: (2024-10-01) -
The Effect of Chemotherapeutic Agents on Survival in Metastatic Non-Small-Cell Lung Cancer with KRAS Mutation
by: Mustafa Emre Duygulu, et al.
Published: (2024-04-01) -
Dynamic circulating tumor DNA indicates pathological benefits of additional neoadjuvant chemoimmunotherapy courses for locally advanced non-small-cell lung cancer patients
by: Dong Lin, et al.
Published: (2025-07-01) -
Impact of Subsequent Treatment on Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Transformed to Small-Cell Lung Cancer
by: Chen CY, et al.
Published: (2025-04-01) -
Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study
by: Jixian Li, et al.
Published: (2025-07-01)